Inventiva Stock (NASDAQ:IVA)
Previous Close
$2.24
52W Range
$2.09 - $4.75
50D Avg
$2.45
200D Avg
$3.44
Market Cap
$115.22M
Avg Vol (3M)
$11.06K
Beta
1.01
Div Yield
-
IVA Company Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| VIGL | Vigil Neuroscience, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| IMCR | Immunocore Holdings plc |
| INBX | Inhibrx, Inc. |
| LIAN | LianBio |
| JANX | Janux Therapeutics, Inc. |
| IPHA | Innate Pharma S.A. |
| HCWB | HCW Biologics Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ACLX | Arcellx, Inc. |
| RZLT | Rezolute, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| PCVX | Vaxcyte, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| VRCA | Verrica Pharmaceuticals Inc. |
| CMPX | Compass Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |